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Introduction: There is increasing evidence that non-invasive imaging modalities such as ultra-
sonography may be able to detect subclinical atherosclerotic lesions, and as such may be
useful tools for risk-stratification. However, the clinical relevance of these observations
remains unknown in patients with COPD. Therefore we investigated the association between
COPD and carotid wall intima-media thickness (IMT) in patients undergoing vascular surgery
and its relationship with mortality in these patients.
Methods: Carotid wall IMT was measured in 585 patients who underwent lower extremity,
aortic aneurysm or stenosis repair. Primary study endpoint was increased carotid wall IMT
which was defined as IMT 1.25 mm. Secondary study endpoints included total and cardiovas-
cular mortality over a mean follow-up of 1.5 years.
Results: Thirty-two percent of patients with mild COPD and 36% of the patients with
moderate/severe COPD had increased carotid wall IMT, while only 23% had an increased
carotid wall IMT in patients without COPD (p< 0.01). COPD was independently associated with
an increased carotid wall IMT (OR 1.60; 95% CI 1.08e2.36). Among patients with COPD,
increased carotid wall IMT was associated with an increased risk of total (HR, 3.18 95% CI
1.93e5.24) and cardiovascular mortality (HR 7.28, 95% CI 3.76e14.07).
Conclusions: COPD is associated with increased carotid wall IMT independent of age and
smoking status. Increased carotid wall IMT is associated with increased total and cardiovas-
cular mortality in patients with COPD suggesting that carotid wall measurements may be a good
biomarker for morbidity and mortality in these patients.
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COPD and carotid wall intima-media thickness 713Introduction the COPD patients. COPD was defined according to the‘There is a growing body of literature that indicates that
chronic obstructive pulmonary disease (COPD) is an inde-
pendent risk factor for cardiovascular disease.1 Forevery 10%
decrease in lung function (as measured by forced expiratory
volume in 1 s, FEV1) cardiovascular mortality increases by
nearly 30%.2 However, aside from FEV1, there are no estab-
lished biomarkers in COPD that can assist clinicians in pre-
dicting which patients will and will not develop
cardiovascular morbidity and mortality, as these patients
(even with established ischemic heart disease) often have
normal lipid profile.3 This makes it difficult for practicing
clinicians to accurately risk-stratify patients and to inter-
vene with cardioprotective interventions (e.g. statins) in
patients at increased risk. There is increasing evidence that
non-invasive imaging modalities such as ultrasonography
maybeable to detect subclinical atherosclerotic lesions, and
as such may be useful tools for risk-stratification.4 Using B-
mode ultrasonography, previous studies have shown that
reduced lung function is related to increased intima-media
thickness (IMT) of the common carotid artery.5e9 However,
the clinical relevance of these observations remains
unknown as previous studies did not evaluate the impact of
increased IMT on hard outcomes such as morbidity and
mortality in these patients. In this report,wedetermined the
relationship of carotid wall IMT with COPD (and its severity)
and with total as well as cardiovascular mortality in patients
undergoing peripheral vascular surgery.
Methods
Patients
The study population was derived from an ongoing study of
patients undergoing vascular surgery involving lower
extremity artery, abdominal aortic aneurysm, abdominal
aortic stenosis or carotid artery repair.10 Beginning 2004,
carotid wall IMT measurements were performed on all
patients. In this paper, we report on 585 consecutive
patients who had this measurement beginning 2004 to May of
2009. We excluded patients who underwent carotid artery
repair. Prior to surgery we obtain baseline characteristics in
all patients from their medical records. Abstracted variables
included age, gender, body mass index (weight divided by
height squared (kg/m2)), current smoking status, diabetes
mellitus (known diabetes, fasting blood glucose 7 mmol/l
or requirement for insulin and/or oral anti-diabetic medi-
cation), hypercholesterolemia (known hypercholesterol-
emia or LDL cholesterol >3.5 mmol/l), renal dysfunction
(creatinine >1.5 mg/dl or known renal dysfunction), stroke
and ischemic heart disease (myocardial infarction, angina
pectoris and/or coronary revascularization). The Medical
Ethics Committee of the hospital was informed about the
study and no official approval was requested per institu-
tional practice.
Chronic obstructive pulmonary disease
The diagnosis of COPD was based on preoperative post-
bronchodilator spirometry which was obtained in 95% ofguidelines of the Global Initiative for Chronic Obstructive
Lung Disease (GOLD): predicted FEV1 <80% of the pre-
dicted FEV1 and FEV1/forced vital capacity (FVC) ratio
<0.70.11 COPD severity was classified into mild COPD
(FEV1/FVC <0.70 and FEV1 80% of the predicted FEV1),
and moderate/severe COPD (FEV1/FVC <0.70 and FEV1
<80% of the predicted FEV1). In patients who did not have
a pulmonary function test, the diagnosis of COPD was
based on symptoms (dyspnea, sputum production, and/or
cough) and use of pulmonary medication (bronchodilators
and corticosteroids).
Carotid wall intima-media thickness
Preoperatively, the carotid wall IMT was measured
according to the ‘Mannheim Carotid Intima-Media Thick-
ness Consensus’ scanning and interpreted according to
protocol recommendations.12 Measurements were taken
at least 10 mm proximal to the carotid bifurcation, in the
near and far wall of the left and right common carotid
artery. Repeated measurements were performed along
a minimum of 10 mm length. Four measurements were
taken from both the left and right common carotid artery
(two in the near and two in the far wall). The maximal
measurement from these eight measurements was used
for analysis. Plaques were excluded from the measure-
ments. Two sonographers, unaware of the clinical infor-
mation for each patient, performed the measurements.
The inter-observer correlation was 96.2%. Using a receiver
operating characteristics (ROC) analysis, an optimal
predictive cutoff value of carotid wall IMT for total and
cardiovascular mortality was determined to be 1.25 mm.
Accordingly patients were categorized into two classes
based on this cutoff and those with IMT 1.25 mm were
deemed to have increased IMT.
Follow-up and outcome
Information on vital status was obtained from the municipal
civil registries. Follow-up was completed in all patients
with a mean follow-up of 1.5 years. Endpoints were total
and cardiovascular mortality 5 years after surgery.
Mortality was considered cardiovascular unless evidence of
a non-cardiovascular cause could be ascertained on review
of medical records or electronic patient files.
Statistical analysis
The differences in baseline characteristics between
patients with and without increased carotid wall IMT were
assessed using Student’s t-test for continuous variables and
a Chi-square test for categorical variables and were pre-
sented as means and percentages, respectively. Mean
carotid IMT values of patients without COPD, mild COPD
and moderate/severe COPD were compared using analysis
of variance. To assess the relationship between COPD
severity (independent variable) and increased IMT
(dependent variable) we used logistic regression analysis.
We determined the relationship between increased carotid
wall IMT and mortality in patients with COPD by employing
714 Y.R.B.M. van Gestel et al.a Cox regression analysis in which adjustments were made
for age, gender, diabetes, hypercholesterolemia, hyper-
tension, renal dysfunction, body mass index, smoking
status, previous ischemic heart disease and stroke. Odds
ratios (OR) and hazard ratios (HR) were provided with their
95% confidence intervals (CI). All tests were two-sided and
p-values <0.05 were considered statistically significant.
Data were analyzed using SPSS 15.0 (SPSS Inc., Chicago,
Illinois, USA) for Windows.
Results
Patients
Baseline characteristics of the 585 patients are shown in
Table 1. In total 164 (28%) patients had increased carotid
wall IMT. COPD was present in 267 (46%) patients; mild
(21%), moderate (20%) and severe COPD (5%). Patients with
increased carotid wall IMT were more likely to be older and
to be male. COPD, renal dysfunction and history of stroke
were also more often present in patients with increased
carotid wall IMT (p< 0.05 for all).Table 1 Baseline characteristics of the study population.
Carotid wal
IMT< 1.25 m
(nZ 421)
Demographics
Mean age (years SD) 67 (11)
Male gender (%) 75
Clinical characteristics
Diabetes mellitus (%) 33
Glucose (mmol/l SD) 6.0 (2.0)
Hypercholesterolemia (%) 65
Total cholesterol (mmol/l SD) 4.8 (1.2)
LDL cholesterol (mmol/l SD) 2.8 (1.1)
HDL cholesterol (mmol/l SD) 1.3 (0.4)
Hypertension 64
Renal dysfunction (%) 20
Body mass index (SD) 26 (4)
Smoking status (%)
Never smoker 21
Current smoker 43
Past smoker 36
Cardiovascular history
Ischemic heart
diseasea (%)
43
Stroke (%) 12
COPD (%)
Mild COPD 20
Moderate/severe COPD 22
a Myocardial infarction, angina pectoris and/or coronary revascularCOPD as risk factor for increased carotid wall IMT
The mean carotid wall IMT of the entire population was
1.07 mm. Of the patients without COPD, 23% demonstrated
increased carotid wall IMT whereas 32% of patients with
mild COPD and 36% of the patients with moderate/severe
COPD had increased IMT (p< 0.01) (Fig. 1). The mean
carotid wall IMT values of these groups were 1.03 mm,
1.11 mm and 1.13 mm, respectively (p< 0.01). Moreover,
intimal thickness was compared between COPD patients
with spirometry (95%) and those with clinical diagnosis of
COPD (5%). The mean carotid wall IMT of these patients was
1.12 mm and 1.09 mm, respectively (pZ 0.78) indicating
no significant difference in IMT between the two
subgroups.
After adjusting for other risk factors, COPD was signifi-
cantly associated with increased carotid wall IMT (OR 1.60
95% CI 1.08e2.36). This association was mainly driven by
patients with moderate/severe COPD (OR 1.70 95% CI
1.08e2.68). Mild COPD, on the other hand, was not signif-
icantly related to increased IMT (OR 1.48 95% CI
0.90e2.42). In a sensitivity analysis, we excluded patientsl Carotid wall p-Value
m IMT 1.25 mm
(nZ 164)
70 (10) <0.01
84 <0.05
34 0.80
5.7 (2.0) 0.14
67 0.63
4.7 (1.3) 0.37
2.9 (1.1) 0.73
1.2 (0.5) 0.83
71 0.09
28 <0.05
26 (3) 0.65
0.91
19
44
37
46 0.50
26 <0.001
<0.01
23
32
ization.
Figure 1 Percentage increased carotid wall IMT according to
COPD severity.
COPD and carotid wall intima-media thickness 715who experienced a previous stroke (nZ 93) and repeated
the analysis. The relationship of COPD with increased
carotid wall IMT was similar to those from the main analysis
(OR 1.82 95% CI 1.18e2.82); for mild COPD the OR was 1.64
(95% CI 0.95e2.83) and the OR for moderate/severe COPD
was 1.99 (95% CI 1.19e3.31). Furthermore a sensitivity
analysis was performed excluding patients with a clinical
diagnosis of COPD instead of spirometry. The results of this
analysis were comparable to the original analysis as well
(OR 1.68 95% CI 1.13e2.49); for mild COPD (OR 1.62 95% CI
0.99e2.68) and for moderate/severe COPD (OR 1.73 95% CI
1.09e2.73).
Association carotid wall IMT and mortality in
patients with COPD
Of the patients with COPD (nZ 267), 72 (27%) died during
the follow-up period (Table 2). The cumulative 5-year
survival curves (total and cardiovascular mortality) of the
COPD patients with and without increased carotid wall IMT
are presented in Fig. 2. After adjusting for possible con-
founding factors, among patients with COPD, increased
carotid wall IMT was associated with an increased risk of
total mortality compared with COPD patients without
increased IMT (HR, 3.18 95% CI 1.93e5.24) (Table 2). When
cardiovascular mortality was considered, a significant
relationship was even more striking (HR 7.28, 95% CI
3.76e14.07).Table 2 Association between carotid wall IMT and
mortality in patients with COPD.
Death N (%) HR [95% CI]
All-cause mortality 72 (27)
COPD, IMT< 1.25 mm 33 (19) 1.00
COPD, IMT 1.25 mm 39 (43) 3.18 [1.93e5.24]
Cardiovascular mortality 51 (19)
COPD, IMT< 1.25 mm 14 (8) 1.00
COPD, IMT 1.25 mm 37 (41) 7.28 [3.76e14.07]
Adjusted for age, gender, smoking status, previous ischemic
heart disease, stroke, renal insufficiency, hypertension, dia-
betes, hypercholesterolemia and body mass index.Discussion
It is now well recognized that cardiovascular disorders are
the leading cause of morbidity and mortality in patients
with moderate COPD. However, there is a paucity of vali-
dated biomarkers that can be used in clinical practice to
accurately risk stratify such patients for early and aggres-
sive interventions. We found that irrespective of smoking
status and other co-morbidities, moderate to severe COPD
was independently associated with increased IMT of the
common carotid artery and COPD patients with increased
IMT, independent of their lung function, had increased risk
of total and cardiovascular mortality compared to COPD
patients with normal IMT.
Our results are consistent with previous studies, con-
ducted largely in healthy subjects, which have demon-
strated an association between reduced lung function and
increased carotid wall IMT.5,7e9,13 However, these studies
were limited in that two studies included only men,5,9 one
did not adjust for smoking status8 and one assessed
atherosclerosis by determining carotid atherosclerotic pla-
ques instead of carotid wall IMT7 and most importantly,
none related the IMT with long-term mortality.
Themechanism for the association of COPDwith increased
carotid wall IMT is not well known. It is generally recognized
that systemic inflammation exists in COPD and is associated
with increased cardiovascular morbidity and mortality.3
However, a previous study indicated that systemic inflam-
matory biomarkers such as C-reactive protein were not asso-
ciated with the progression of carotid wall IMT,14 suggesting
that other potential mechanisms are involved. Another
possibility could be shared risk factors between COPD and
carotid disease such as smoking. In our analysis, however, we
adjusted for smoking status and still found a significant rela-
tionship betweenCOPDand increased carotidwall IMTarguing
against this theory. In addition, a recent study showed that
meancarotid IMTinmale smokerswithairflowobstructionwas
greater than that of control smokers and never smokers,
suggesting that airflow limitation rather than smoking per se is
associated with atherosclerosis.5
Whatever the mechanism, our study indicates that
carotid IMT is a surrogate for future mortality of patients
with COPD. Since IMT measurements are non-invasive,
reproducible, accessible (in most vascular laboratories) and
can be performed quickly and relatively inexpensively,
these data suggest that carotid IMT is a very promising
biomarker to risk-stratify patients with COPD for mortality
and in particular for cardiovascular mortality, which affects
30e50% of COPD patients.15,16
There are some limitations to this study. Our study was
conducted in patients who underwent surgery for their
peripheral arterial disease and were at increased risk of
cardiovascular mortality. Secondly, the cross-sectional
design of the study precludes attribution of causality
between COPD and IMT. Thirdly, as we did not measure
serum or plasma biomarkers of inflammatory or oxidative
pathways, we could not assess the importance of these
pathways in the relationship of COPD with carotid wall IMT.
Fourthly, COPD was not confirmed spirometrically in 5% of
the patients. However, inclusion or exclusion of such
patients makes little difference to the overall results.
Figure 2 KaplaneMeier survival curves for long-term outcome in patients with COPD.
716 Y.R.B.M. van Gestel et al.In conclusion, the results of this study showed that, after
adjustment for other important risk factors such as smoking,
COPD was associated with increased carotid wall IMT. In
addition, increased carotid wall IMT was related with
increased all-cause and cardiovascular mortality in patients
with COPD. These data raise the possibility of using carotid
wall IMT for risk-stratification in patients with COPD.
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